MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 THIO-101 clinical trial. The trial evaluated the efficacy of their lead clinical candidate, ateganosine (THIO), in combination with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo®) for patients with advanced non-small cell lung cancer (NSCLC) resistant to prior therapies. The latest data reveals a median overall survival $(OS)$ of 17.8 months for patients receiving at least one dose of ateganosine, significantly outperforming the typical 5 to 6 months OS seen in standard-of-care chemotherapy for similar cases. These findings suggest that ateganosine may considerably impact the NSCLC treatment landscape, with potential for accelerated FDA approval and exclusivity. The treatment has been generally well-tolerated in this heavily pre-treated patient population.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。